Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.
2.

mRNA-based approach to monitor recombinant gamma-interferon restoration of LPS-induced endotoxin tolerance.

Turrel-Davin F, Venet F, Monnin C, Barbalat V, Cerrato E, Pachot A, Lepape A, Alberti-Segui C, Monneret G.

Crit Care. 2011;15(5):R252. doi: 10.1186/cc10513.

3.

Identification of biomarkers of response to IFNg during endotoxin tolerance: application to septic shock.

Allantaz-Frager F, Turrel-Davin F, Venet F, Monnin C, De Saint Jean A, Barbalat V, Cerrato E, Pachot A, Lepape A, Monneret G.

PLoS One. 2013 Jul 11;8(7):e68218. doi: 10.1371/journal.pone.0068218. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/5cdfb251-b4ab-4346-b64d-589a3344ef78.

4.

Early biomarker activity in severe sepsis and septic shock and a contemporary review of immunotherapy trials: not a time to give up, but to give it earlier.

Rivers EP, Jaehne AK, Nguyen HB, Papamatheakis DG, Singer D, Yang JJ, Brown S, Klausner H.

Shock. 2013 Feb;39(2):127-37. doi: 10.1097/SHK.0b013e31827dafa7. Review.

PMID:
23324881
5.

Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression.

Pachot A, Cazalis MA, Venet F, Turrel F, Faudot C, Voirin N, Diasparra J, Bourgoin N, Poitevin F, Mougin B, Lepape A, Monneret G.

J Immunol. 2008 May 1;180(9):6421-9.

6.

Emerging therapies for sepsis and septic shock.

Oh HM.

Ann Acad Med Singapore. 1998 Sep;27(5):738-43. Review.

PMID:
9919353
7.
8.

Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis.

Monneret G, Debard AL, Venet F, Bohe J, Hequet O, Bienvenu J, Lepape A.

Crit Care Med. 2003 Jul;31(7):2068-71.

PMID:
12847405
9.

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

Vincent JL, Sun Q, Dubois MJ.

Clin Infect Dis. 2002 Apr 15;34(8):1084-93. Review.

PMID:
11914997
10.

Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options.

Hamers L, Kox M, Pickkers P.

Minerva Anestesiol. 2015 Apr;81(4):426-39. Review.

11.

Angiopoietin-2 is increased in septic shock: evidence for the existence of a circulating factor stimulating its release from human monocytes.

Kranidioti H, Orfanos SE, Vaki I, Kotanidou A, Raftogiannis M, Dimopoulou I, Kotsaki A, Savva A, Papapetropoulos A, Armaganidis A, Giamarellos-Bourboulis EJ.

Immunol Lett. 2009 Jun 30;125(1):65-71. doi: 10.1016/j.imlet.2009.06.006.

PMID:
19539650
12.

Attenuation of catecholamine-induced immunosuppression in whole blood from patients with sepsis.

Bergmann M, Gornikiewicz A, Sautner T, Waldmann E, Weber T, Mittlböck M, Roth E, Függer R.

Shock. 1999 Dec;12(6):421-7.

PMID:
10588509
13.
14.

Comparison of monocyte functions after LPS- or IL-10-induced reorientation: importance in clinical immunoparalysis.

Wolk K, Döcke W, von Baehr V, Volk H, Sabat R.

Pathobiology. 1999;67(5-6):253-6.

PMID:
10725796
15.

New strategies in nonantibiotic treatment of gram-negative sepsis.

Cohn J, Bone RC.

Cleve Clin J Med. 1992 Nov-Dec;59(6):608-15. Review.

PMID:
1424072
16.

Immunomodulatory therapies in sepsis.

Kox WJ, Volk T, Kox SN, Volk HD.

Intensive Care Med. 2000;26 Suppl 1:S124-8. Review.

PMID:
10786969
17.

Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients.

Pachot A, Monneret G, Brion A, Venet F, Bohé J, Bienvenu J, Mougin B, Lepape A.

Crit Care Med. 2005 Jan;33(1):31-8; discussion 236-7.

PMID:
15644645
18.

The future is predetermined in severe sepsis, so what are the implications?

Lukaszewicz AC, Payen D.

Crit Care Med. 2010 Oct;38(10 Suppl):S512-7. doi: 10.1097/CCM.0b013e3181f23dc4. Review.

PMID:
21164390
19.

Sepsis and septic shock. II. Treatment.

Mayer J, Hajek R, Vorlicek J, Tomiska M.

Support Care Cancer. 1995 Mar;3(2):111-9. Review.

PMID:
7773578
20.

Immunotherapy of sepsis syndrome: a comparison of the available treatments.

Fisher CJ Jr, Bellingan G.

Klin Wochenschr. 1991;69 Suppl 26:162-7. Review.

PMID:
1813714

Supplemental Content

Support Center